Internal Medicine (Dept. of Endocrinology and Diabetology, Angiology, Nephrology and Clinical Chemistry), University of Tuebingen, Otfried-Muellerstrasse 10, 72076 Tuebingen, Germany; Center for Medical Research, Medical University Graz, Stiftingtalstr. 24, 8010 Graz, Austria.
Internal Medicine (Dept. of Endocrinology and Diabetology, Angiology, Nephrology and Clinical Chemistry), University of Tuebingen, Otfried-Muellerstrasse 10, 72076 Tuebingen, Germany.
Front Neuroendocrinol. 2019 Jan;52:29-43. doi: 10.1016/j.yfrne.2018.06.006. Epub 2018 Jun 22.
Thyrotropin-releasing hormone (TRH) causes a variety of thyroidal and non-thyroidal effects, the best known being the feedback regulation of thyroid hormone levels. This was employed in the TRH stimulation test, which is currently little used. The role of TRH as a cancer biomarker is minor, but exaggerated responses to TSH and prolactin levels in breast cancer led to the hypothesis of a potential role for TRH in the pathogenesis of this disease. TRH is a rapidly degraded peptide with multiple targets, limiting its suitability as a biomarker and drug candidate. Although some studies reported efficacy in neural diseases (depression, spinal cord injury, amyotrophic lateral sclerosis, etc.), therapeutic use of TRH is presently restricted to spinocerebellar degenerative disease. Regulation of TRH production in the hypothalamus, patterns of expression of TRH and its receptor in the body, its role in energy metabolism and in prolactin secretion are addressed in this review.
促甲状腺激素释放激素 (TRH) 可引起多种甲状腺和非甲状腺作用,其中最为人熟知的是甲状腺激素水平的反馈调节。这一作用被用于 TRH 刺激试验中,目前该试验的应用较少。TRH 作为癌症生物标志物的作用较小,但乳腺癌对 TSH 和催乳素水平的反应过度,导致了 TRH 在该疾病发病机制中可能发挥作用的假说。TRH 是一种具有多种靶标的快速降解肽,限制了其作为生物标志物和药物候选物的适用性。尽管一些研究报告了在神经疾病(抑郁症、脊髓损伤、肌萎缩侧索硬化症等)中的疗效,但 TRH 的治疗用途目前仅限于脊髓小脑退行性疾病。本文综述了下丘脑 TRH 产生的调节、TRH 及其受体在体内的表达模式、在能量代谢和催乳素分泌中的作用。